Company / Operating Cash Flow per Share
Apellis Pharmaceuticals, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$0.36
FY2025
5-year range
-$7.40 / $0.36
FY2021-FY2025
Trend
+149.5%
vs FY2024
Sector context
#67 of 212
Health Care
What the data says
At $0.36, Apellis Pharmaceuticals, Inc.'s operating cash flow per share ranks #67 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-7.40 in FY2021 to $0.36 in FY2025.
Based on SEC 10-K filings.
0.36 in FY2025.
Improved from $-5.37 to $0.36 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#67 of 212 in Health CareTop 32% of 212This company $0.36 Sector average -$14.72
▼
+102.5% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 149.5% year-over-year.
- Ranks #67 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.36 | +149.5% |
| FY2024 | -$0.73 | +86.3% |
| FY2023 | -$5.37 | -1.9% |
| FY2022 | -$5.27 | +28.8% |
| FY2021 | -$7.40 | -194.7% |
| FY2020 | -$2.51 | +26.0% |
| FY2019 | -$3.39 | -40.6% |
| FY2018 | -$2.41 | +28.2% |
| FY2017 | -$3.36 | -8.9% |
| FY2016 | -$3.09 | +5.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026